<DOC>
	<DOC>NCT01111110</DOC>
	<brief_summary>Delivery of HFA albuterol through an antistatic valved holding chamber (VHC) will improve bronchodilator response during nocturnal bronchospasm.</brief_summary>
	<brief_title>Response to Albuterol Delivered Through an Anti-static Valved Holding Chamber During Nocturnal Bronchospasm</brief_title>
	<detailed_description />
	<mesh_term>Bronchial Spasm</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Age 1865 years. Physician diagnosis of asthma. FEV1 6080% predicted during the day. FEV1 increases ≥ 12 % and to ≥ 80% predicted after 2 4 puffs of albuterol HFA MDI delivered by antistatic VHC. No smoking in the previous year and &lt; 10pack year history. No history of severe asthma attacks requiring ER visit or hospitalization in the previous three months. Patient required a short course of oral steroid in the past 30 days. Any disease that is inadequately controlled or any medication that would worsen asthma or interact with asthma medications. History of viral respiratory tract infection in the 3 weeks prior to the screening visit. Positive pregnancy test.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
</DOC>